

# Rosalie Liccardo Pacula

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5337063/publications.pdf>

Version: 2024-02-01

95  
papers

5,752  
citations

87888

38  
h-index

88630

70  
g-index

106  
all docs

106  
docs citations

106  
times ranked

3996  
citing authors

#	ARTICLE	IF	CITATIONS
1	Lower-Risk Cannabis Use Guidelines (LRCUG) for reducing health harms from non-medical cannabis use: A comprehensive evidence and recommendations update. <i>International Journal of Drug Policy</i> , 2022, 99, 103381.	3.3	75
2	The International Cannabis Toolkit (iCannToolkit): a multidisciplinary expert consensus on minimum standards for measuring cannabis use. <i>Addiction</i> , 2022, 117, 1510-1517.	3.3	44
3	Cannabis flower prices and transitions to legal sources after legalization in Canada, 2019–2020. <i>Drug and Alcohol Dependence</i> , 2022, 231, 109262.	3.2	14
4	Comparison of hospital claims and poison center data to evaluate health impact of opioids, cannabis and synthetic cannabinoids. <i>American Journal of Emergency Medicine</i> , 2022, 53, 150-153.	1.6	2
5	Cannabis legalization and cannabis-involved pregnancy hospitalizations in Colorado. <i>Preventive Medicine</i> , 2022, 156, 106993.	3.4	6
6	Relationships of Cannabis Policy Liberalization With Alcohol Use and Co-Use With Cannabis: A Narrative Review. <i>Alcohol Research: Current Reviews</i> , 2022, 41, 06.	3.6	12
7	The iCannToolkit: a tool to embrace measurement of medicinal and non-medical cannabis use across licit, illicit and cross-cultural settings. <i>Addiction</i> , 2022, , .	3.3	3
8	Prices and Purchase Sources for Dried Cannabis Flower in the United States, 2019–2020. <i>Cannabis and Cannabinoid Research</i> , 2022, , .	2.9	0
9	Impact of cannabis legalization on healthcare utilization for psychosis and schizophrenia in Colorado. <i>International Journal of Drug Policy</i> , 2022, 104, 103685.	3.3	10
10	Comparison of Medical Cannabis Use Reported on a Confidential Survey vs Documented in the Electronic Health Record Among Primary Care Patients. <i>JAMA Network Open</i> , 2022, 5, e2211677.	5.9	19
11	Rating the comparative efficacy of state-level cannabis policies on recreational cannabis markets in the United States. <i>International Journal of Drug Policy</i> , 2022, 106, 103744.	3.3	3
12	California Cannabis Markets—Why Industry-Friendly Regulation Is Not Good Public Health. <i>JAMA Health Forum</i> , 2022, 3, e222018.	2.2	6
13	The need to more effectively regulate END markets: A primary public health lesson of the U.S. vaping associated lung injury outbreak. <i>Addiction</i> , 2021, 116, 994-995.	3.3	3
14	Causes and Consequences of Illicit Drug Epidemics. , 2021, , 1-37.		0
15	The Evolving Consequences of OxyContin Reformulation on Drug Overdoses. <i>American Journal of Health Economics</i> , 2021, 7, 41-67.	3.0	29
16	Data Needs in Opioid Systems Modeling: Challenges and Future Directions. <i>American Journal of Preventive Medicine</i> , 2021, 60, e95-e105.	3.0	15
17	Internet search and medicaid prescription drug data as predictors of opioid emergency department visits. <i>Npj Digital Medicine</i> , 2021, 4, 21.	10.9	5
18	Commentary on Rychert and Wilkins (2021) –Why did New Zealand's referendum to legalise recreational cannabis fail?™. <i>Drug and Alcohol Review</i> , 2021, 40, 884-885.	2.1	1

#	ARTICLE	IF	CITATIONS
19	Current U.S. State Cannabis Sales Limits Allow Large Doses for Use or Diversion. <i>American Journal of Preventive Medicine</i> , 2021, 60, 701-705.	3.0	9
20	Assessment of Recreational Cannabis Dispensaries'™ Compliance With Underage Access and Marketing Restrictions in California. <i>JAMA Pediatrics</i> , 2021, 175, 1178.	6.2	13
21	Changes in Emergency Department Encounters for Vomiting After Cannabis Legalization in Colorado. <i>JAMA Network Open</i> , 2021, 4, e2125063.	5.9	18
22	Claims-based measures of prescription opioid utilization: A practical guide for researchers. <i>Drug and Alcohol Dependence</i> , 2021, 228, 109087.	3.2	3
23	Moving beyond the classic difference-in-differences model: a simulation study comparing statistical methods for estimating effectiveness of state-level policies. <i>BMC Medical Research Methodology</i> , 2021, 21, 279.	3.1	10
24	How increasing medical access to opioids contributes to the opioid epidemic: Evidence from Medicare Part D. <i>Journal of Health Economics</i> , 2020, 71, 102286.	2.7	36
25	The state of the science in opioid policy research. <i>Drug and Alcohol Dependence</i> , 2020, 214, 108137.	3.2	26
26	The impacts of potency, warning messages, and price on preferences for Cannabis flower products. <i>International Journal of Drug Policy</i> , 2019, 74, 1-10.	3.3	25
27	Early evidence of the impact of cannabis legalization on cannabis use, cannabis use disorder, and the use of other substances: Findings from state policy evaluations. <i>American Journal of Drug and Alcohol Abuse</i> , 2019, 45, 644-663.	2.1	180
28	Association Between State Laws Facilitating Pharmacy Distribution of Naloxone and Risk of Fatal Overdose. <i>JAMA Internal Medicine</i> , 2019, 179, 805.	5.1	165
29	State-Level Approaches to Expanding Pharmacists'™ Authority to Dispense Naloxone May Affect Accessibility"Reply. <i>JAMA Internal Medicine</i> , 2019, 179, 1443.	5.1	1
30	Prevalence of Cannabis Use in Youths After Legalization in Washington State. <i>JAMA Pediatrics</i> , 2019, 173, 192.	6.2	85
31	Medical marijuana laws and adolescent marijuana use in the United States: a systematic review and meta-analysis. <i>Addiction</i> , 2018, 113, 1003-1016.	3.3	142
32	RESPONSES TO QUESTIONS ON POLICING AND INSURANCE BENEFIT DESIGN AS THEY PERTAIN TO THE OPIOID CRISIS. <i>Journal of Policy Analysis and Management</i> , 2018, 37, 449-451.	1.4	0
33	A SUPPLY-SIDE PERSPECTIVE ON THE OPIOID CRISIS. <i>Journal of Policy Analysis and Management</i> , 2018, 37, 438-446.	1.4	29
34	Do medical marijuana laws reduce addictions and deaths related to pain killers?. <i>Journal of Health Economics</i> , 2018, 58, 29-42.	2.7	248
35	Supply-Side Drug Policy in the Presence of Substitutes: Evidence from the Introduction of Abuse-Deterrent Opioids. <i>American Economic Journal: Economic Policy</i> , 2018, 10, 1-35.	3.1	119
36	A Population-Based Examination of Trends and Disparities in Medication Treatment for Opioid use Disorders among Medicaid Enrollees. <i>Substance Abuse</i> , 2018, 39, 419-425.	2.3	87

#	ARTICLE	IF	CITATIONS
37	Cannabis and the Opioid Crisis. Cannabis and Cannabinoid Research, 2018, 3, 108-116.	2.9	10
38	Does Mandatory Diversion to Drug Treatment Eliminate Racial Disparities in the Incarceration of Drug Offenders? An Examination of California's Proposition 36. Journal of Quantitative Criminology, 2017, 33, 179-205.	2.9	9
39	Medical Marijuana and Marijuana Legalization. Annual Review of Clinical Psychology, 2017, 13, 397-419.	12.3	201
40	Early Impacts of Marijuana Legalization: An Evaluation of Prices in Colorado and Washington. Journal of Primary Prevention, 2017, 38, 221-248.	1.6	44
41	Understanding and learning from the diversification of cannabis supply laws. Addiction, 2017, 112, 1128-1135.	3.3	53
42	Building the data infrastructure to evaluate cannabis legalization. Addiction, 2017, 112, 1140-1141.	3.3	6
43	Advancing knowledge on cannabis policy using evidence from North America. International Journal of Drug Policy, 2017, 42, 36-38.	3.3	6
44	Association of State Recreational Marijuana Laws With Adolescent Marijuana Use. JAMA Pediatrics, 2017, 171, 142.	6.2	313
45	Mapping medical marijuana: state laws regulating patients, product safety, supply chains and dispensaries, 2017. Addiction, 2017, 112, 2206-2216.	3.3	75
46	Did the dependent coverage expansion increase risky substance use among young adults?. Drug and Alcohol Dependence, 2017, 178, 556-561.	3.2	4
47	Opioid analgesic and benzodiazepine prescribing among Medicaid-enrollees with opioid use disorders: The influence of provider communities. Journal of Addictive Diseases, 2017, 36, 14-22.	1.3	31
48	A Systematic Review of the Prevention and Treatment of Prescription Drug Misuse. Military Medicine, 2016, 181, 410-423.	0.8	10
49	In the weeds: a baseline view of cannabis use among legalizing states and their neighbours. Addiction, 2016, 111, 973-980.	3.3	105
50	Physician Capacity to Treat Opioid Use Disorder With Buprenorphine-Assisted Treatment. JAMA - Journal of the American Medical Association, 2016, 316, 1211.	7.4	99
51	Where Is Buprenorphine Dispensed to Treat Opioid Use Disorders? The Role of Private Offices, Opioid Treatment Programs, and Substance Abuse Treatment Facilities in Urban and Rural Counties. Milbank Quarterly, 2015, 93, 561-583.	4.4	89
52	Assessing the Effects of Medical Marijuana Laws on Marijuana Use: The Devil is in the Details. Journal of Policy Analysis and Management, 2015, 34, 7-31.	1.4	319
53	The price elasticity of demand for heroin: Matched longitudinal and experimental evidence. Journal of Health Economics, 2015, 41, 59-71.	2.7	14
54	Medical marijuana laws and adolescent marijuana use in the USA from 1991 to 2014: results from annual, repeated cross-sectional surveys. Lancet Psychiatry, the, 2015, 2, 601-608.	7.4	226

#	ARTICLE	IF	CITATIONS
55	Supply of buprenorphine waived physicians: The influence of state policies. Journal of Substance Abuse Treatment, 2015, 48, 104-111.	2.8	96
56	Considering Marijuana Legalization: Insights for Vermont and Other Jurisdictions. , 2015, , .		86
57	Decomposing Racial Disparities in Prison and Drug Treatment Commitments for Criminal Offenders in California. Journal of Legal Studies, 2014, 43, 155-187.	0.4	19
58	Words Can Be Deceiving: A Review of Variation among Legally Effective Medical Marijuana Laws in the United States. Journal of Drug Policy Analysis, 2014, 7, 1-19.	0.5	80
59	Marijuana Liberalization Policies: Why We Can't Learn Much from Policy Still in Motion. Journal of Policy Analysis and Management, 2014, 33, 212-221.	1.4	115
60	Natural Experiments in a Complex and Dynamic Environment: The Need for a Measured Assessment of the Evidence. Journal of Policy Analysis and Management, 2014, 33, 232-235.	1.4	18
61	The effects of medical marijuana laws on potency. International Journal of Drug Policy, 2014, 25, 308-319.	3.3	102
62	Developing Public Health Regulations for Marijuana: Lessons From Alcohol and Tobacco. American Journal of Public Health, 2014, 104, 1021-1028.	2.7	190
63	Economic Analysis and Policy Studies: Special Challenges in the Prevention Sciences. , 2014, , 571-596.		1
64	Why Changes in Price Matter When Thinking About Marijuana Policy: A Review of the Literature on the Elasticity of Demand. Public Health Reviews, 2013, 35, 1-18.	3.2	107
65	Design considerations for legalizing cannabis: lessons inspired by analysis of California's Proposition 19. Addiction, 2012, 107, 865-871.	3.3	62
66	Heterogeneity in the composition of marijuana seized in California. Drug and Alcohol Dependence, 2011, 117, 59-61.	3.2	77
67	Bringing perspective to illicit markets: Estimating the size of the U.S. marijuana market. Drug and Alcohol Dependence, 2011, 119, 153-160.	3.2	33
68	Addiction Research Centres and the Nurturing of Creativity. RAND's Drug Policy Research Center. Addiction, 2011, 106, 253-259.	3.3	0
69	Substance use and recessions: What can be learned from economic analyses of alcohol?. International Journal of Drug Policy, 2011, 22, 326-334.	3.3	29
70	An Analysis of Applicants Presenting to a Medical Marijuana Specialty Practice in California. Journal of Drug Policy Analysis, 2011, 4, .	0.5	91
71	Invisible wounds, visible savings? Using microsimulation to estimate the costs and savings associated with providing evidence-based treatment for PTSD and depression to veterans of Operation Enduring Freedom and Operation Iraqi Freedom.. Psychological Trauma: Theory, Research, Practice, and Policy, 2011, 3, 201-211.	2.1	30
72	Marijuana use and high school dropout: the influence of unobservables. Health Economics (United Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	1.7	80

#	ARTICLE	IF	CITATIONS
73	Risks and Prices: The Role of User Sanctions in Marijuana Markets. B E Journal of Economic Analysis and Policy, 2010, 10, .	0.9	38
74	Do Citizens Know Whether Their State Has Decriminalized Marijuana? Assessing the Perceptual Component of Deterrence Theory. Review of Law and Economics, 2009, 5, .	0.3	54
75	The incremental inpatient costs associated with marijuana comorbidity. Drug and Alcohol Dependence, 2008, 92, 248-257.	3.2	12
76	Do Citizens Know Whether Their State Has Decriminalized Marijuana? A Test of the Perceptual Assumption in Deterrence Theory. SSRN Electronic Journal, 2008, , .	0.4	1
77	Racial differences in marijuana-usersâ€™ risk of arrest in the United States. Drug and Alcohol Dependence, 2006, 84, 264-272.	3.2	78
78	Is the drug court model exportable? The cost-effectiveness of a driving-under-the-influence court. Journal of Substance Abuse Treatment, 2006, 31, 75-85.	2.8	21
79	College Students' Use of Cocaine. Substance Use and Misuse, 2006, 41, 489-509.	1.4	41
80	Limits of Current Economic Analyses of the Demand for Illicit Drugs. Substance Use and Misuse, 2006, 41, 607-609.	1.4	1
81	Marijuana Markets: Inferences from Reports by the Household Population. Journal of Drug Issues, 2006, 36, 173-200.	1.2	122
82	What we can-and cannot-expect from school-based drug prevention. Drug and Alcohol Review, 2004, 23, 79-87.	2.1	88
83	Alcohol and marijuana use among college students: economic complements or substitutes?. Health Economics (United Kingdom), 2004, 13, 825-843.	1.7	137
84	State Medical Marijuana Laws: Understanding the Laws and Their Limitations. Journal of Public Health Policy, 2002, 23, 413.	2.0	57
85	State medical marijuana laws: understanding the laws and their limitations. Journal of Public Health Policy, 2002, 23, 413-39.	2.0	24
86	THE EFFECTS OF MACRO-LEVEL INTERVENTIONS ON ADDICTIVE BEHAVIOR. Substance Use and Misuse, 2001, 36, 1901-1922.	1.4	32
87	Does the sunset of mental health parity really matter?. Administration and Policy in Mental Health and Mental Health Services Research, 2001, 28, 353-369.	2.1	16
88	Datapoints: Mental Health Parity and Employer-Sponsored Health Insurance in 1999-2000: I. Limits. Psychiatric Services, 2000, 51, 1361-1361.	2.0	9
89	Datapoints: Mental Health Parity and Employer-Sponsored Health Insurance in 1999-2000: II. Copayments and Coinsurance. Psychiatric Services, 2000, 51, 1487-1487.	2.0	6
90	State Mental Health Parity Laws: Cause Or Consequence Of Differences In Use?. Health Affairs, 1999, 18, 182-192.	5.2	130

#	ARTICLE	IF	CITATIONS
91	Datapoints: Labor Force Participation by Persons With Mental Illness. <i>Psychiatric Services</i> , 1999, 50, 1407-1407.	2.0	43
92	Does increasing the beer tax reduce marijuana consumption?. <i>Journal of Health Economics</i> , 1998, 17, 557-585.	2.7	218
93	Letter: Economic modelling of the gateway effect. , 1997, 6, 521-524.		28
94	Marijuana and Youth. , 0, , 271-326.		31
95	The Economic Modeling of the Gateway Effect. <i>SSRN Electronic Journal</i> , 0, , .	0.4	1